Inogen Inc (INGN) - Net Assets
Based on the latest financial reports, Inogen Inc (INGN) has net assets worth $182.91 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($285.93 Million) and total liabilities ($103.02 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Inogen Inc tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $182.91 Million |
| % of Total Assets | 63.97% |
| Annual Growth Rate | 26.0% |
| 5-Year Change | -48.08% |
| 10-Year Change | 5.57% |
| Growth Volatility | 76.46 |
Inogen Inc - Net Assets Trend (2011–2025)
This chart illustrates how Inogen Inc's net assets have evolved over time, based on quarterly financial data. See how many days can Inogen Inc fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Inogen Inc (2011–2025)
The table below shows the annual net assets of Inogen Inc from 2011 to 2025. For live valuation and market cap data, see how much is Inogen Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $192.23 Million | +10.57% |
| 2024-12-31 | $173.86 Million | -15.11% |
| 2023-12-31 | $204.81 Million | -31.13% |
| 2022-12-31 | $297.41 Million | -19.67% |
| 2021-12-31 | $370.23 Million | +5.89% |
| 2020-12-31 | $349.62 Million | +1.45% |
| 2019-12-31 | $344.62 Million | +11.02% |
| 2018-12-31 | $310.42 Million | +36.73% |
| 2017-12-31 | $227.04 Million | +24.69% |
| 2016-12-31 | $182.09 Million | +35.87% |
| 2015-12-31 | $134.02 Million | +13.43% |
| 2014-12-31 | $118.15 Million | +109.86% |
| 2013-12-31 | $56.30 Million | +97.02% |
| 2012-12-31 | $28.57 Million | +278.18% |
| 2011-12-31 | $7.56 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Inogen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9977000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $27.00K | 0.01% |
| Other Comprehensive Income | $4.24 Million | 2.21% |
| Other Components | $363.55 Million | 189.12% |
| Total Equity | $192.23 Million | 100.00% |
Inogen Inc Competitors by Market Cap
The table below lists competitors of Inogen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AVITA Medical Inc
F:51KB
|
$172.49 Million |
|
Adairs Ltd
AU:ADH
|
$172.51 Million |
|
Taylor Devices Inc
NASDAQ:TAYD
|
$172.51 Million |
|
Hanyang Securities Co Ltd
KO:001755
|
$172.52 Million |
|
Robot Consulting Co., Ltd. ADS
NASDAQ:LAWR
|
$172.35 Million |
|
Cambridge Acquisition Corp. Class A Ordinary Shares
NASDAQ:CAQ
|
$172.33 Million |
|
LIWANLI Innovation Co Ltd
TW:3054
|
$172.28 Million |
|
New World Resources Ltd
AU:NWC
|
$172.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Inogen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 173,860,000 to 192,231,000, a change of 18,371,000 (10.6%).
- Net loss of 22,747,000 reduced equity.
- New share issuances of 27,210,000 increased equity.
- Other comprehensive income increased equity by 5,744,000.
- Other factors increased equity by 8,164,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-22.75 Million | -11.83% |
| Share Issuances | $27.21 Million | +14.15% |
| Other Comprehensive Income | $5.74 Million | +2.99% |
| Other Changes | $8.16 Million | +4.25% |
| Total Change | $- | 10.57% |
Book Value vs Market Value Analysis
This analysis compares Inogen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.90x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 13.78x to 0.90x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $0.46 | $6.37 | x |
| 2012-12-31 | $1.75 | $6.37 | x |
| 2013-12-31 | $3.12 | $6.37 | x |
| 2014-12-31 | $6.55 | $6.37 | x |
| 2015-12-31 | $6.47 | $6.37 | x |
| 2016-12-31 | $8.63 | $6.37 | x |
| 2017-12-31 | $10.37 | $6.37 | x |
| 2018-12-31 | $13.79 | $6.37 | x |
| 2019-12-31 | $15.49 | $6.37 | x |
| 2020-12-31 | $15.91 | $6.37 | x |
| 2021-12-31 | $16.46 | $6.37 | x |
| 2022-12-31 | $13.01 | $6.37 | x |
| 2023-12-31 | $8.84 | $6.37 | x |
| 2024-12-31 | $7.35 | $6.37 | x |
| 2025-12-31 | $7.07 | $6.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Inogen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -11.83%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.52%
- • Asset Turnover: 1.17x
- • Equity Multiplier: 1.55x
- Recent ROE (-11.83%) is below the historical average (-2.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -26.50% | -6.54% | 1.27x | 3.19x | $-2.76 Million |
| 2012 | 1.97% | 1.16% | 1.02x | 1.67x | $-2.29 Million |
| 2013 | 45.18% | 33.71% | 0.92x | 1.46x | $19.81 Million |
| 2014 | 5.78% | 6.07% | 0.80x | 1.19x | $-4.99 Million |
| 2015 | 8.64% | 7.29% | 0.99x | 1.20x | $-1.82 Million |
| 2016 | 11.27% | 10.12% | 0.95x | 1.18x | $2.31 Million |
| 2017 | 9.25% | 8.42% | 0.91x | 1.21x | $-1.70 Million |
| 2018 | 16.70% | 14.48% | 0.95x | 1.21x | $20.80 Million |
| 2019 | 6.08% | 5.79% | 0.81x | 1.30x | $-13.51 Million |
| 2020 | -1.67% | -1.89% | 0.67x | 1.32x | $-40.79 Million |
| 2021 | -1.71% | -1.77% | 0.73x | 1.32x | $-43.36 Million |
| 2022 | -28.17% | -22.21% | 0.93x | 1.36x | $-113.51 Million |
| 2023 | -50.02% | -32.46% | 0.97x | 1.59x | $-122.93 Million |
| 2024 | -20.64% | -10.69% | 1.13x | 1.70x | $-53.27 Million |
| 2025 | -11.83% | -6.52% | 1.17x | 1.55x | $-41.97 Million |
Industry Comparison
This section compares Inogen Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,818,520,110
- Average return on equity (ROE) among peers: -48.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Inogen Inc (INGN) | $182.91 Million | -26.50% | 0.56x | $172.46 Million |
| Abbott Laboratories (ABT) | $17.78 Billion | 20.28% | 1.23x | $153.89 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $15.55 Million |
| Aethlon Medical Inc (AEMD) | $-5.98 Million | 0.00% | 0.00x | $2.51 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $903.35K |
| Adapthealth Corp (AHCO) | $280.85 Million | -57.55% | 5.46x | $1.29 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $6.89 Million | 30.07% | 0.49x | $6.67 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $7.70 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $8.10 Million | -140.88% | 0.21x | $4.44 Million |
| Artivion Inc (AORT) | $17.90 Million | 7.26% | 0.20x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $22.89 Million | 2.69% | 0.23x | $176.29 Million |
About Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen the… Read more